US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
US6858615B2
(en)
|
2002-02-19 |
2005-02-22 |
Parion Sciences, Inc. |
Phenyl guanidine sodium channel blockers
|
AU2004272599A1
(en)
|
2003-09-06 |
2005-03-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
DE602004022319D1
(de)
*
|
2003-11-14 |
2009-09-10 |
Vertex Pharma |
Thiazole udn oxazole als modulatoren von atp-bindungs-kassetten-transportern
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
EP2522659A3
(fr)
*
|
2004-06-24 |
2013-11-27 |
Vertex Pharmaceuticals Incorporated |
Modulateurs de transporteurs de cassette de liaison a l´ATP
|
EP1912983B1
(fr)
|
2005-08-11 |
2011-06-08 |
Vertex Pharmaceuticals, Inc. |
Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
|
PL2774925T3
(pl)
|
2005-11-08 |
2017-07-31 |
Vertex Pharmaceuticals Incorporated |
Heterocykliczne modulatory transporterów z kasetą wiążącą ATP
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
CN101384172B
(zh)
*
|
2005-12-28 |
2014-05-07 |
沃泰克斯药物股份有限公司 |
N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式
|
EP2016065B1
(fr)
*
|
2005-12-28 |
2012-09-19 |
Vertex Pharmaceuticals Incorporated |
Dérivés de la 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide et composés similaires en tant que modulateurs des transporteurs de cassettes de liaison de l'atp pour le traitement de la fibrose cystique
|
EP3327016B1
(fr)
|
2006-04-07 |
2021-06-16 |
Vertex Pharmaceuticals Incorporated |
Préparation des modulateurs de transporteurs de cassette à liaison atp
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
CA2652072A1
(fr)
*
|
2006-05-12 |
2007-11-22 |
Vertex Pharmaceuticals Incorporated |
Compositions de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoleine-3-carboxamide
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
CN102863432B
(zh)
|
2007-05-09 |
2016-09-07 |
沃泰克斯药物股份有限公司 |
Cftr调节剂
|
ES2578735T3
(es)
|
2007-08-24 |
2016-07-29 |
Vertex Pharmaceuticals Incorporated |
Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística
|
WO2009049159A1
(fr)
*
|
2007-10-10 |
2009-04-16 |
Parion Sciences, Inc. |
Administration d'osmolytes par canule nasale
|
WO2009064959A1
(fr)
*
|
2007-11-16 |
2009-05-22 |
Vertex Pharmaceuticals Incorporated |
Modulateurs d'isoquinoléine de transporteurs de cassette de liaison à l'atp
|
NZ585794A
(en)
*
|
2007-12-07 |
2012-05-25 |
Vertex Pharma |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
EA201070699A1
(ru)
*
|
2007-12-07 |
2011-02-28 |
Вертекс Фармасьютикалз Инкорпорейтед |
Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
|
US20100036130A1
(en)
*
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
EP2225230B1
(fr)
|
2007-12-07 |
2016-11-16 |
Vertex Pharmaceuticals Incorporated |
Formes solides d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
|
NZ587545A
(en)
|
2008-02-28 |
2012-09-28 |
Vertex Pharma |
Heteroaryl derivatives as cftr modulators
|
NZ600772A
(en)
|
2008-03-31 |
2013-10-25 |
Vertex Pharma |
Pyridyl derivatives as CFTR modulators
|
US20100256184A1
(en)
*
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
EP2349223A2
(fr)
*
|
2008-09-29 |
2011-08-03 |
Vertex Pharmaceuticals Incorporated |
Unités posologiques d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
|
JP5645833B2
(ja)
|
2008-10-23 |
2014-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
嚢胞性線維症膜コンダクタンス制御因子の修飾因子
|
SI2408750T1
(sl)
*
|
2009-03-20 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
|
CN102665715A
(zh)
*
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
DK2555754T3
(en)
|
2010-04-07 |
2016-04-18 |
Vertex Pharma |
Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
|
HUE056525T2
(hu)
|
2010-04-07 |
2022-02-28 |
Vertex Pharma |
3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
|
EP2560954B1
(fr)
|
2010-04-22 |
2016-10-05 |
Vertex Pharmaceuticals Incorporated |
Procédé de production de composés de cycloalkylcarboxamido-indole
|
EP2560650A1
(fr)
|
2010-04-22 |
2013-02-27 |
Vertex Pharmaceuticals Incorporated |
Compositions pharmaceutiques et leurs administrations
|
NZ603042A
(en)
|
2010-04-22 |
2015-02-27 |
Vertex Pharma |
Pharmaceutical compositions comprising cftr modulators and administrations thereof
|
NZ603386A
(en)
*
|
2010-05-20 |
2015-02-27 |
Vertex Pharma |
Pharmaceutical compositions and administrations thereof
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
PT2709986T
(pt)
|
2011-05-18 |
2017-06-26 |
Concert Pharmaceuticals Inc |
Derivados deuterados de ivacaftor
|
CA2838529C
(fr)
|
2011-06-07 |
2020-03-24 |
Parion Sciences, Inc. |
Procedes de traitement
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
CA2852991C
(fr)
|
2011-11-08 |
2019-12-31 |
Vertex Pharmaceuticals Incorporated |
Modulateurs de transporteurs de cassette de liaison a l'atp
|
WO2013130669A1
(fr)
|
2012-02-27 |
2013-09-06 |
Vertex Pharmaceuticals Incorporated |
Composition pharmaceutique et son administration
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
EA032734B1
(ru)
|
2012-05-29 |
2019-07-31 |
Парион Сайэнс, Инк. |
Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек
|
WO2014014841A1
(fr)
|
2012-07-16 |
2014-01-23 |
Vertex Pharmaceuticals Incorporated |
Compositions pharmaceutiques de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl)cyclopropane- carboxamide et leur administration
|
WO2014078842A1
(fr)
|
2012-11-19 |
2014-05-22 |
Concert Pharmaceuticals, Inc. |
Potentialisateurs de cftr deutérés
|
CA2896686A1
(fr)
|
2012-12-17 |
2014-06-26 |
Parion Sciences, Inc. |
Composes 3,5-diamino -6-chloro-n-(n- (4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide
|
CN104995178B
(zh)
|
2012-12-17 |
2018-06-26 |
帕里昂科学公司 |
3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
|
GEP20186903B
(en)
|
2012-12-17 |
2018-10-25 |
Saiensis Ink Perion |
Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
|
MX365950B
(es)
|
2013-03-13 |
2019-06-19 |
Flatley Discovery Lab Llc |
Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
|
DK3068392T5
(da)
|
2013-11-12 |
2021-09-20 |
Vertex Pharma |
Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
|
US9102633B2
(en)
|
2013-12-13 |
2015-08-11 |
Parion Sciences, Inc. |
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
|
CN103787968B
(zh)
*
|
2014-02-27 |
2016-04-13 |
上海湖发化学技术有限公司 |
化合物的制备方法
|
JP6543268B2
(ja)
|
2014-04-15 |
2019-07-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
EP4159717A1
(fr)
|
2014-10-06 |
2023-04-05 |
Vertex Pharmaceuticals Incorporated |
Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique
|
WO2016057730A1
(fr)
*
|
2014-10-07 |
2016-04-14 |
Strohmeier Mark |
Co-cristaux de modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
|
SI3221692T1
(sl)
|
2014-11-18 |
2021-11-30 |
Vertex Pharmaceuticals Inc. |
Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo
|
GB201504878D0
(en)
|
2015-03-23 |
2015-05-06 |
Algipharma As |
Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
|
US10759721B2
(en)
|
2015-09-25 |
2020-09-01 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated CFTR potentiators
|
GB201517639D0
(en)
|
2015-10-06 |
2015-11-18 |
Algipharma As |
Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
|
CN106187887B
(zh)
*
|
2016-07-01 |
2018-08-14 |
上海工程技术大学 |
4-羟基喹啉-3-甲酸的制备方法
|
PT3519401T
(pt)
|
2016-09-30 |
2021-12-27 |
Vertex Pharma |
Modulador de regulador de condutância transmembranar de fibrose quística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador
|
SI3551622T1
(sl)
|
2016-12-09 |
2021-02-26 |
Vertex Pharmaceuticals Incorporated |
Modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in postopek izdelave modulatorja
|
WO2018227049A1
(fr)
|
2017-06-08 |
2018-12-13 |
Vertex Pharmaceuticals Incorporated |
Méthodes de traitement de la fibrose kystique
|
US20210069174A1
(en)
|
2017-07-01 |
2021-03-11 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of cystic fibrosis
|
WO2019018353A1
(fr)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
Méthodes de traitement de la fibrose kystique
|
MA49631A
(fr)
|
2017-07-17 |
2020-05-27 |
Vertex Pharma |
Méthodes de traitement de la fibrose kystique
|
AU2018309043B2
(en)
|
2017-08-02 |
2022-03-31 |
Vertex Pharmaceuticals Incorporated |
Processes for preparing pyrrolidine compounds
|
MX2020004034A
(es)
*
|
2017-10-18 |
2020-08-13 |
Jiangsu Hengrui Medicine Co |
Metodo de preparacion para un inhibidor de tirosina cinasa e intermediario del mismo.
|
CA3078893A1
(fr)
|
2017-10-19 |
2019-04-25 |
Vertex Pharmaceuticals Incorporated |
Formes cristallines et compositions de modulateurs de cftr
|
CN117924170A
(zh)
|
2017-12-01 |
2024-04-26 |
弗特克斯药品有限公司 |
用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
|
US20210228489A1
(en)
|
2017-12-04 |
2021-07-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
MA51039A
(fr)
|
2017-12-08 |
2020-10-14 |
Vertex Pharma |
Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
CN112004817B
(zh)
|
2018-02-15 |
2023-06-23 |
弗特克斯药品有限公司 |
作为cftr的调节剂的大环化合物、其药物组合物、它们的用途和制备方法
|
US20210139514A1
(en)
|
2018-04-05 |
2021-05-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP3774825A1
(fr)
|
2018-04-13 |
2021-02-17 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
|
WO2020102346A1
(fr)
|
2018-11-14 |
2020-05-22 |
Vertex Pharmaceuticals Incorporated |
Méthodes de traitement de la fibrose kystique
|
AR118555A1
(es)
|
2019-04-03 |
2021-10-20 |
Vertex Pharma |
Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
WO2020214921A1
(fr)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Formes solides de modulateurs de cftr
|
WO2020226889A1
(fr)
*
|
2019-05-07 |
2020-11-12 |
Wellstat Therapeutics Corporation |
Formulations d'uridine triacétate dans de la triacétine
|
WO2020242935A1
(fr)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Méthodes de traitement de la mucoviscidose
|
CN114585628B
(zh)
|
2019-08-14 |
2024-03-26 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调节因子的调节剂
|
AU2020328028A1
(en)
|
2019-08-14 |
2022-03-17 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of CFTR modulators
|
TW202120517A
(zh)
|
2019-08-14 |
2021-06-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
TW202115092A
(zh)
|
2019-08-14 |
2021-04-16 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白之調節劑
|
WO2022194399A1
(fr)
|
2020-07-13 |
2022-09-22 |
Idorsia Pharmaceuticals Ltd |
Macrocycles en tant que modulateurs de cftr
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
US20230303589A1
(en)
|
2020-08-13 |
2023-09-28 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of cftr modulators
|
CA3197683A1
(fr)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
|
US20230373935A1
(en)
|
2020-10-07 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
IL301756A
(en)
|
2020-10-07 |
2023-05-01 |
Vertex Pharma |
Cystic fibrosis transmembrane regulator conductance modulators
|
EP4225737A1
(fr)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
|
WO2022076624A1
(fr)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du régulateur de conductance transmembranaire de la fibrose kystique
|
US20230382924A1
(en)
|
2020-10-07 |
2023-11-30 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2022076629A1
(fr)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
|
WO2022076618A1
(fr)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
|
EP4225763A1
(fr)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du régulateur de conductance transmembranaire de la fibrose kystique
|
US20240189299A1
(en)
*
|
2021-03-09 |
2024-06-13 |
Laurus Labs Limited |
Oral film of cftr modulator(s)
|
WO2023150237A1
(fr)
|
2022-02-03 |
2023-08-10 |
Vertex Pharmaceuticals Incorporated |
Méthodes de traitement de la fibrose kystique
|
WO2023154291A1
(fr)
|
2022-02-08 |
2023-08-17 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
|
WO2023196429A1
(fr)
|
2022-04-06 |
2023-10-12 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
|
WO2023224931A1
(fr)
|
2022-05-16 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Méthodes de traitement de la fibrose kystique
|
EP4335434A1
(fr)
|
2022-08-17 |
2024-03-13 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Compositions pharmaceutiques comprenant l'ivacaftor
|
WO2024056798A1
(fr)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Modulateurs du cftr macrocycliques
|
WO2024056791A1
(fr)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Association de modulateurs de cftr macrocycliques avec des correcteurs de cftr et/ou des potentialisateurs de cftr
|
WO2024056779A1
(fr)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Forme cristalline de (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-méthoxy-1,2,4-oxadiazol-5-yl)éthyl)-6,9-diméthyl-1,5,8,11-tétraoxo-10-(2,2,2-trifluoroéthyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tétradecahydro-[1]oxa[4,7,10,14]tétraazacycloheptadécino [16,17-f]quinoléine-3-carboxamide
|